VYNE Therapeutics Inc. [NASDAQ: VYNE] gained 5.10% or 0.08 points to close at $1.65 with a heavy trading volume of 1765834 shares.
It opened the trading session at $1.59, the shares rose to $1.675 and dropped to $1.55, the range by which the price of stock traded the whole day. The daily chart for VYNE points out that the company has recorded -38.43% loss over the past six months. However, it is still -65.0% lower than its most recent low trading price.
If we look at the average trading volume of 2.39M shares, VYNE reached to a volume of 1765834 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about VYNE Therapeutics Inc. [VYNE]:
The Average True Range (ATR) for VYNE Therapeutics Inc. is set at 0.15, with the Price to Sales ratio for VYNE stock in the period of the last 12 months amounting to 22.01. The Price to Book ratio for the last quarter was 3.17, with the Price to Cash per share for the same quarter was set at 0.54.
Trading performance analysis for VYNE stock
VYNE Therapeutics Inc. [VYNE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.94. With this latest performance, VYNE shares gained by 11.49% in over the last four-week period, additionally sinking by -38.43% over the last 6 months – not to mention a drop of -63.17% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VYNE stock in for the last two-week period is set at 53.28, with the RSI for the last a single of trading hit 53.75, and the three-weeks RSI is set at 51.42 for VYNE Therapeutics Inc. [VYNE]. The present Moving Average for the last 50 days of trading for this stock 1.6027, while it was recorded at 1.5760 for the last single week of trading, and 2.7502 for the last 200 days.
VYNE Therapeutics Inc. [VYNE]: A deeper dive into fundamental analysis
VYNE Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.70 and a Current Ratio set at 4.90.
VYNE Therapeutics Inc. [VYNE]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, VYNE Therapeutics Inc. posted -0.7/share EPS, while the average EPS was predicted by analysts to be reported at -0.77/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 9.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VYNE.
An analysis of insider ownership at VYNE Therapeutics Inc. [VYNE]
There are presently around $139 million, or 52.20% of VYNE stock, in the hands of institutional investors. The top three institutional holders of VYNE stocks are: PERCEPTIVE ADVISORS LLC with ownership of 22,876,410, which is approximately 244.671% of the company’s market cap and around 2.10% of the total institutional ownership; BLACKROCK INC., holding 8,213,551 shares of the stock with an approximate value of $13.55 million in VYNE stocks shares; and VANGUARD GROUP INC, currently with $11.55 million in VYNE stock with ownership of nearly 587.543% of the company’s market capitalization.
95 institutional holders increased their position in VYNE Therapeutics Inc. [NASDAQ:VYNE] by around 58,144,388 shares. Additionally, 35 investors decreased positions by around 8,736,963 shares, while 2 investors held positions by with 17,648,530 shares. The mentioned changes placed institutional holdings at 84,529,881 shares, according to the latest SEC report filing. VYNE stock had 35 new institutional investments in for a total of 13,124,146 shares, while 24 institutional investors sold positions of 7,169,132 shares during the same period.